From Medscape Oncology

Medscape Medical News from the:

2012 European Society for Medical Oncology (ESMO) Congress

September 28 - October 2, 2012; Vienna, Austria

This coverage is not sanctioned by, nor a part of the European Society for Medical Oncology.

Meeting Highlights at a Glance

Top News From ESMO 2012: Slideshow
Highlights of the meeting include that 1 year of trastuzumab therapy remains the standard for HER2+ breast cancer; many women who are eligible for breast-conserving surgery aren't being offered it; and crizotinib is now the standard-of-care for ALK+ non-small-cell lung cancer.

Conference News

Medscape Oncology Insights

High PROFILE for Crizotinib in NSCLC
Giorgio V. Scagliotti, MD;
Tony Mok, MD

BEV: New Standard in Resistant Ovarian Cancer?
Stanley B. Kaye, MD

Bortezomib Combo Keeps on Giving in Myeloma
Martin Dreyling, MD

ESMO: Lung and Breast Cancer Studies Top the Bill
Josep Tabernero, MD
Martine J. Piccart, MD, PhD

Fine-Tuning Neoadjuvant Therapy in Breast Cancer
Fabrice André, MD, PhD
Ian E. Smith, MD

New Agents Show Activity in Prostate Cancer
Johann S. de Bono, MBChB, PhD, MSc
Howard I. Scher, MD

EGFR Inhibition: Does It Have a Role in GI Cancer?
David J. Kerr, MD
Josep Tabernero, MD

 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.